Related Experiment Video
Updated: Jul 16, 2026

Isolation of Double Negative αβ T Cells from the Kidney
Published on: May 16, 2014
The apoptosis-1/Fas protein in human systemic lupus erythematosus
1Hospital for Special Surgery, Cornell University Medical Center, New York 10021.
Abstract:
Three independent mutations involving the apoptosis-1 (APO-1)/Fas receptor or its putative ligand have led to lupuslike diseases associated with lymphadenopathy in different strains of mice. To determine whether humans with SLE also have a defect in this apotosis pathway, we analyzed the expression of APO-1 on freshly isolated blood mononuclear cells and on lymphocytes activated in vitro using flow cytometry and the monoclonal antibody anti-APO-1. Significantly higher level of APO-1 expression were detected on freshly isolated peripheral B cells and both CD4+ and CD8+ T lymphocyte populations obtained from lupus patients when compared with normal controls (P < 0.001). Almost 90% of the cells that stained positive for APO-1 also expressed the CD29 antigen, suggesting that APO-1 was upregulated after lymphocyte activation in vivo. No defect in APO-1 regulation was detected after activation of SLE T (with anti-CD3) or B (with Staphylococcus aureus Cowan 1) lymphocytes in the presence of IL-2 in vitro. Similarly, the anti-APO-1 antibody induced apoptosis in 74 +/- 5% of activated SLE T cells in vitro compared with 79 +/- 6% of the normal controls (P > 0.05). These results reveal that, while APO-1/Fas may play an important role in the regulation of lymphocyte survival in SLE, no consistent defect in the expression or function of the receptor could be detected in these studies.
Insights
Systemic lupus erythematosus (SLE) patients show higher APO-1/Fas receptor expression on lymphocytes, but no functional defect was found in this apoptosis pathway in vitro.
Area of Science:
- Immunology
- Cell Biology
- Molecular Medicine
Background:
- Mutations in the APO-1/Fas receptor pathway cause lupus-like disease in mice.
- Investigating the role of this apoptosis pathway in human Systemic Lupus Erythematosus (SLE) is crucial.
Purpose of the Study:
- To determine if humans with SLE have defects in the APO-1/Fas mediated apoptosis pathway.
- To analyze APO-1 receptor expression and function on lymphocytes from SLE patients.
Main Methods:
- Flow cytometry and anti-APO-1 antibody were used to analyze APO-1 expression on freshly isolated and in vitro activated blood mononuclear cells.
- Analysis included peripheral B cells, CD4+ and CD8+ T lymphocytes.
- Apoptosis induction by anti-APO-1 antibody was assessed in activated SLE and normal lymphocytes.
Main Results:
- Significantly higher APO-1 expression was observed on freshly isolated B cells and T lymphocytes from SLE patients compared to controls (P < 0.001).
- APO-1 upregulation was linked to in vivo lymphocyte activation, as indicated by co-expression with CD29.
- No defects in APO-1 regulation or function (apoptosis induction) were detected in vitro in activated SLE lymphocytes.
Conclusions:
- While APO-1/Fas signaling is important for lymphocyte survival in SLE, this study found no consistent defect in receptor expression or function in vitro.
- Further research is needed to fully elucidate the role of the APO-1/Fas pathway in SLE pathogenesis.
Related Concept Videos
Apoptosis
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Cellular Injury V: Apoptosis and Autophagy

